Validation of MS110, an Antibody to BRCA-1 for Immunohistochemistry.
H Wombwell , M O'Connor , C Harbron , B Spaulding
Pathological Society of Great Britain and Ireland
2011
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Avinash Gupta , Christopher Towers , Frances Willenbrock , Roz Brant
British Journal of Cancer 122 ( 4) 506 -516
18
2020
Process for providing a filled canister for an inhaler
Simon Christopher Berry , Agnes Claude Marcelle Pierrette Colombani , Duncan Charles Dickie , Ian Flecther
8
2011
Characterisation of natural and recombinant homologues of a toxic phospholipase
Darren Richard Hodgson
University of Newcastle upon Tyne
1992
Hair is a viable surrogate tissue for routine measurement of gene expression in clinical studies
Carolyn Haggerty , Athula Herath , Darren Hodgson , Patricia Hurley
Molecular Cancer Therapeutics 6
2007
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
Johanne I Weberpals , Trevor J Pugh , Paola Marco‐Casanova , Glenwood D Goss
Cancer Medicine 10 ( 9) 3045 -3058
2021
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Aude Fléchon , Daniel Petrylak , Petros Grivas , Alain Ravaud
Nature Medicine 27 ( 5) 793 -801
45
2021
Abstract C130: Plucked human scalp hairs: Potential utility as a surrogate tissue for the assessment of therapies targeting the androgen receptor
Jim Growcott , Ged Brady , Karen Pickering , Jill Walker
Molecular Cancer Therapeutics 8
2009
Abstract C119: Identification of gene expression biomarkers that predict sensitivity to the PARP inhibitor olaparib
Alan Lau , Jonathan Dry , Chris Harbron , Charlotte Knights
Molecular Cancer Therapeutics 8
2009
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
Jonathan R. Dry , Sandra Pavey , Christine A. Pratilas , Chris Harbron
Cancer Research 70 ( 6) 2264 -2273
186
2010
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A Ledermann , Philipp Harter , Charlie Gourley , Michael Friedlander
The Lancet Oncology 17 ( 11) 1579 -1589
238
2016
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang , Rui-Hua Xu , Keisho Chin , Keun-Wook Lee
The Lancet Oncology 18 ( 12) 1637 -1651
128
2017
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke , Pawel Wiechno , Boris Alekseev , Nuria Sala
Lancet Oncology 19 ( 7) 975 -986
291
2018
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer
Hiroyuki Nomura , Fumio Kataoka , Daisuke Aoki , Hiromitsu Jinno
Cancer Biomarkers 16 ( 1) 145 -152
4
2016
Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients
Hee Sung Kim , Min A Kim , Darren Hodgson , Christopher Harbron
Pathobiology 80 ( 3) 127 -137
38
2013
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang , Seock-Ah Im , Keun-Wook Lee , Jae Yong Cho
Journal of Clinical Oncology 33 ( 33) 3858 -3865
161
2015
Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer
Jonathan Ledermann , Philipp Harter , Charlie Gourley , Michael Friedlander
Obstetrical & Gynecological Survey 69 ( 10) 594 -596
6
2014
Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY).
Danielle Carroll , Rob McEwen , Iwanka Kozarewa , Elizabeth Harrington
Journal of Clinical Oncology 37 4553 -4553
2019
Assessment of 5-methylcytosine and 5-hydroxymethylcytosine technologies in contrived ctDNA-like samples.
Eun-Ang Raiber-Moreau , James Hadfield , Darren Hodgson , Marilou Wijdicks
Journal of Clinical Oncology 38 ( 15_suppl) e15585 -e15585
2020
Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.
Sonia Eckersley , Donna Barnes , Juli Warwicker , Erica Van Dorp
Virchows Archiv 462 ( 3) 269 -279
20
2013